Experimental brain cancer therapy targets tumors directly
NCT ID NCT07386002
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called MT027 for people with recurrent glioblastoma, an aggressive brain cancer. MT027 uses specially engineered immune cells (UCAR-T cells) that are injected directly into the fluid around the brain. The trial will include 40 adults aged 18-70 and aims to check safety and whether it helps patients live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT027 UCAR-T cells (a type of immune cell therapy) targeting B7H3
What this could lead to
If successful, this could offer a new treatment option for people with recurrent glioblastoma, potentially extending survival.
What could go wrong
This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The treatment involves direct brain injection and carries risks like brain swelling or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital, Kaohsiung
Kaohsiung City, 833401, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Chang Gung Memorial Hospital, Linkou
Taoyuan, 333423, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hualien Tzu Chi Hospital
Hualien City, 970473, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact